Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice.

Marino JS, Peterson SJ, Li M, Vanella L, Sodhi K, Hill JW, Abraham NG.

Nutr Diabetes. 2012 Mar 12;2:e33. doi: 10.1038/nutd.2012.4.

2.

The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice.

Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L'Abbate A, Abraham NG.

J Lipid Res. 2009 Jul;50(7):1293-304. doi: 10.1194/jlr.M800610-JLR200. Epub 2009 Feb 17.

3.

L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.

Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG.

J Lipid Res. 2008 Aug;49(8):1658-69. doi: 10.1194/jlr.M800046-JLR200. Epub 2008 Apr 19.

4.

Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice.

Vecoli C, Cao J, Neglia D, Inoue K, Sodhi K, Vanella L, Gabrielson KK, Bedja D, Paolocci N, L'abbate A, Abraham NG.

J Cell Biochem. 2011 Sep;112(9):2616-26. doi: 10.1002/jcb.23188.

5.

ApoA1: mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in heme oxygenase (HO-1) and Wnt10b.

Vanella L, Li M, Kim D, Malfa G, Bellner L, Kawakami T, Abraham NG.

Cell Cycle. 2012 Feb 15;11(4):706-14. doi: 10.4161/cc.11.4.19125. Epub 2012 Feb 15.

6.

Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance.

Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, Aronow WS, Ikehara S, Abraham NG.

Diabetes. 2008 Jun;57(6):1526-35. doi: 10.2337/db07-1764. Epub 2008 Mar 28.

7.

Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice.

Burgess A, Li M, Vanella L, Kim DH, Rezzani R, Rodella L, Sodhi K, Canestraro M, Martasek P, Peterson SJ, Kappas A, Abraham NG.

Hypertension. 2010 Dec;56(6):1124-30. doi: 10.1161/HYPERTENSIONAHA.110.151423. Epub 2010 Nov 1.

8.

Apo A1 Mimetic Rescues the Diabetic Phenotype of HO-2 Knockout Mice via an Increase in HO-1 Adiponectin and LKBI Signaling Pathway.

Cao J, Puri N, Sodhi K, Bellner L, Abraham NG, Kappas A.

Int J Hypertens. 2012;2012:628147. doi: 10.1155/2012/628147. Epub 2012 Apr 4.

9.

Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.

Sherman CB, Peterson SJ, Frishman WH.

Cardiol Rev. 2010 May-Jun;18(3):141-7. doi: 10.1097/CRD.0b013e3181c4b508. Review.

PMID:
20395699
10.

Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls.

Nassis GP, Papantakou K, Skenderi K, Triandafillopoulou M, Kavouras SA, Yannakoulia M, Chrousos GP, Sidossis LS.

Metabolism. 2005 Nov;54(11):1472-9.

PMID:
16253636
11.

Impact of exercise training without caloric restriction on inflammation, insulin resistance and visceral fat mass in obese adolescents.

Mendelson M, Michallet AS, Monneret D, Perrin C, Estève F, Lombard PR, Faure P, Lévy P, Favre-Juvin A, Pépin JL, Wuyam B, Flore P.

Pediatr Obes. 2015 Aug;10(4):311-9. doi: 10.1111/ijpo.255. Epub 2014 Aug 4.

PMID:
25088157
12.

Glycine regulates the production of pro-inflammatory cytokines in lean and monosodium glutamate-obese mice.

Alarcon-Aguilar FJ, Almanza-Perez J, Blancas G, Angeles S, Garcia-Macedo R, Roman R, Cruz M.

Eur J Pharmacol. 2008 Dec 3;599(1-3):152-8. doi: 10.1016/j.ejphar.2008.09.047. Epub 2008 Oct 9.

PMID:
18930730
13.

L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.

Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA Jr.

Circulation. 2003 May 13;107(18):2337-41. Epub 2003 May 5.

14.

Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice.

Delporte ML, El Mkadem SA, Quisquater M, Brichard SM.

Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E446-53. Epub 2004 May 4.

15.

Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients.

Filippidis G, Liakopoulos V, Mertens PR, Kiropoulos T, Stakias N, Verikouki C, Patsidis E, Koukoulis G, Stefanidis I.

Blood Purif. 2005;23(6):421-8. Epub 2005 Sep 2.

PMID:
16141714
16.

Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice.

Liu X, Xue Y, Liu C, Lou Q, Wang J, Yanagita T, Xue C, Wang Y.

Lipids Health Dis. 2013 Jul 23;12:109. doi: 10.1186/1476-511X-12-109.

17.

Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.

Malloy VL, Perrone CE, Mattocks DA, Ables GP, Caliendo NS, Orentreich DS, Orentreich N.

Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5.

PMID:
23928105
18.

Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.

Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP.

Arthritis Res Ther. 2010;12(3):R93. doi: 10.1186/ar3020. Epub 2010 May 18.

19.

Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.

Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr.

Circ Res. 2005 Nov 25;97(11):1190-7. Epub 2005 Oct 13.

20.

Elevated visfatin levels in obese children are related to proinflammatory factors.

Li RZ, Ma Xn, Hu XF, Kang SX, Chen SK, Cianflone K, Lu HL.

J Pediatr Endocrinol Metab. 2013;26(1-2):111-8.

PMID:
23327785

Supplemental Content

Support Center